Krebs Biochemicals Announces Audited Financial Results for FY26 and Q4 Results
Krebs Biochemicals & Industries Ltd. announced its audited financial results for the fourth quarter and the full financial year ending March 31, 2026. The company also released its audited balance sheet and cash flow statement for the fiscal period.The results provide a comprehensive view of the company's performance across the year, with the financials prepared in accordance with Indian Accounting Standards (IND AS).
Key Financial Highlights
The company reported its total income of 2,575.79 lacs for the year ended March 31, 2026. This figure compares to 4,402.08 lacs reported in the previous year for the same period.In the fourth quarter alone (ended March 31, 2026), the company reported a Total Income of 881.27 lacs. During the same quarter in the previous year, the Total Income was 727.85 lacs.
The company also disclosed its Standalone Cash Flow Statement, showing that the Net Cash Flow from Operating Activities for the year ended March 31, 2026, was (192.05) lacs, compared to (789.10) lacs for the year ended March 31, 2025.
Financial Statements Summary
The audited financials, presented in lacs, detail the key performance indicators for the company.Statement of Audited Standalone Financial Results (Rs. In lacs)
| Statement Item | Quarter Ended 31.03.2026 | Quarter Ended 31.12.2025 | Quarter Ended 31.03.25 | Year Ended 31.03.2026 | Year Ended 31.03.2025 |
|---|---|---|---|---|---|
| Revenue from Operations | 680.91 | 727.42 | 610.05 | 2,373.16 | 4,331.19 |
| Other Income | 200.36 | 0.43 | 33.80 | 202.63 | 70.89 |
| Total Income | 881.27 | 727.85 | 643.85 | 2,575.79 | 4,402.08 |
| Total Expenses | 1,115.23 | 1,040.49 | 1,469.16 | 4,269.10 | 7,094.48 |
| Profit/(Loss) for the period (Continuing Operations) | (233.96) | (312.65) | (825.31) | (1,693.31) | (2,693.93) |
| Total Comprehensive Income for the period | 1,192.24 | 1,312.65 | 1,835.13 | 11,651.59 | (2,702.21) |
Balance Sheet and Assets Overview
The Balance Sheet shows the company's total assets stood at 16,324.67 lacs as of March 31, 2026, compared to 16,903.56 lacs on the same date in the previous year.Standalone Statement of Assets and Liabilities (Rs. In Lacs)
| Particulars | As at 31.03.2026 | As at 31.03.2025 |
|---|---|---|
| Total Assets | 16,324.67 | 16,903.56 |
| Total Non-current assets | 15,362.45 | 15,877.65 |
| Total Current assets | 962.22 | 1,025.91 |
| Total Equity and Liabilities | 16,324.67 | 16,903.56 |
| Total Equity | (16,275.47) | (14,623.88) |
| Total Non-current liabilities | 21,293.56 | 21,174.83 |
| Total Current liabilities | 11,306.58 | 10,352.61 |
Operational Status Update
The company noted that its operations at the Vizag manufacturing unit remain closed, a status implemented pursuant to an order dated February 7, 2025, passed by the Andhra Pradesh Pollution Control Board. The company stated that it is in dialogue with the Pollution Control Board regarding the revocation of the closure order.KREBSBIO Stock Price Movement
Shares of Krebs Biochemicals and Industries Limited are edging higher to ₹55.3 as of 2:23 PM, advancing 0.25% in live trading. Trading on a volume of 1,243 shares, the stock maintains momentum in the live market.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.